MKI-1, an MASTL Inhibitor, Exerts Antitumor and Radiosensitizer Activities
Mitosis is an attractive target for selective anticancer treatment. Mitotic kinases, including CDKs, AURKs, and PLK1, associate with tumor progression and prognosis. However, these agents are cytotoxicity to healthy cells. inhibitors against…